THTX vs. ENGN, TSHA, BTMD, TNGX, ATYR, ITOS, TRVI, DSGN, AVIR, and AQST
Should you be buying Theratechnologies stock or one of its competitors? The main competitors of Theratechnologies include enGene (ENGN), Taysha Gene Therapies (TSHA), biote (BTMD), Tango Therapeutics (TNGX), Atyr PHARMA (ATYR), iTeos Therapeutics (ITOS), Trevi Therapeutics (TRVI), Design Therapeutics (DSGN), Atea Pharmaceuticals (AVIR), and Aquestive Therapeutics (AQST). These companies are all part of the "pharmaceutical products" industry.
Theratechnologies vs.
enGene (NASDAQ:ENGN) and Theratechnologies (NASDAQ:THTX) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, profitability, dividends, media sentiment, community ranking, risk, analyst recommendations, earnings and institutional ownership.
64.2% of enGene shares are owned by institutional investors. 13.7% of enGene shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
In the previous week, enGene had 3 more articles in the media than Theratechnologies. MarketBeat recorded 6 mentions for enGene and 3 mentions for Theratechnologies. Theratechnologies' average media sentiment score of 0.75 beat enGene's score of -0.31 indicating that Theratechnologies is being referred to more favorably in the news media.
enGene has a net margin of 0.00% compared to Theratechnologies' net margin of -3.75%. Theratechnologies' return on equity of 0.00% beat enGene's return on equity.
enGene currently has a consensus target price of $29.78, suggesting a potential upside of 325.03%. Given enGene's stronger consensus rating and higher probable upside, equities research analysts plainly believe enGene is more favorable than Theratechnologies.
enGene has a beta of -0.65, indicating that its stock price is 165% less volatile than the S&P 500. Comparatively, Theratechnologies has a beta of 1.3, indicating that its stock price is 30% more volatile than the S&P 500.
Theratechnologies received 13 more outperform votes than enGene when rated by MarketBeat users. However, 100.00% of users gave enGene an outperform vote while only 52.73% of users gave Theratechnologies an outperform vote.
Theratechnologies has higher revenue and earnings than enGene. Theratechnologies is trading at a lower price-to-earnings ratio than enGene, indicating that it is currently the more affordable of the two stocks.
Summary
enGene beats Theratechnologies on 10 of the 18 factors compared between the two stocks.
Get Theratechnologies News Delivered to You Automatically
Sign up to receive the latest news and ratings for THTX and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Theratechnologies Competitors List
Related Companies and Tools
This page (NASDAQ:THTX) was last updated on 1/22/2025 by MarketBeat.com Staff
